Your search matched 9 results
An update on the latest developments in Washington critical to Pharma leaders.
The U.S. | Blog
Democrats have revealed that the next major legislative package—colloquially known as the infrastructure package—will likely include provisions to lower prescription drug prices.
Within a few days of the Aduhelm approval, the conversation quickly shifted from the first treatment for Alzheimer’s disease to the exorbitant cost ($56,000 annually) and whether the budgetary impact on society of the drug’s broad label is worth the therapeutic outcomes.
EFPIA W.A.I.T. | Blog
The European Federation of Pharmaceutical Industries and Association (EFPIA) Waiting to Access Innovative Therapies (W.A.I.T.)
The World Orphan Drug Congress Europe (WODC) looked back on the remarkable achievements of the last 20 years of the General Pharmaceutical Legislation (GPL) in Europe.
As you may have read, the Biden administration announced last week that it will support a proposal to temporarily waive certain intellectual property (IP) protections for COVID-19 vaccines and therapies.
This month, we’ve seen a flurry of activity that confirms Washington will be focused on drug pricing this summer, and it’s coming from all directions: Congress, the Biden Administration, and Courts.
In a highly anticipated decision, the Food and Drug Administration (FDA) last week cleared Alzheimer’s disease drug aducanumab on an accelerated, conditional approval program.
This month policies aimed at lowering drug prices are back on the table.